Unlearn.AI vs Anthropic
Side-by-side comparison of AI visibility scores, market position, and capabilities
Unlearn.AI raised $50M+ for its digital twin technology that creates AI-generated control arms for clinical trials, reducing placebo group size and accelerating drug development timelines.
About
Unlearn.AI generates digital twins of clinical trial patients — AI models trained on historical trial data that predict how a specific patient would have responded as a placebo control. By supplementing small placebo control groups with these digital controls, pharmaceutical companies can run trials with fewer placebo patients (or none at all), reducing participant burden, trial costs, and development timelines without sacrificing statistical validity.
Claude 4 family (claude-opus-4-6, claude-sonnet-4-6, claude-haiku-4-5) at $5B ARR (2025); $183B valuation (Series F, Sept 2025); $14.3B raised — Amazon $8B, Google $2B; Claude Code at $500M+ ARR; 300K+ business customers; Claude.ai 18M+ MAU; competing with OpenAI o3/GPT-4.5, Google Gemini 2.0, Meta Llama 4.
About
Anthropic is a San Francisco-based AI safety and research company that builds the Claude family of large language models. As of 2026, the current Claude 4 generation includes claude-opus-4-6 (most capable, reasoning and agentic tasks), claude-sonnet-4-6 (balanced performance and speed), and claude-haiku-4-5 (fast and cost-efficient). Anthropic also offers Claude Code — an agentic CLI for software engineering — generating $500M+ ARR by mid-2025.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.